相关实验视频
Updated: Jul 6, 2025

09:17
Using Retinal Imaging to Study Dementia
Published on: November 6, 2017
21.6K
移民和获得痴呆症诊断和治疗:瑞典的一项全国性研究
Minh Tuan Hoang1, Ingemar Kåreholt2,3, Emma Lindgren4
1Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.
SSM - population health
|January 1, 2024
概括
与瑞典出生的人相比,外国出生的个人在痴呆症诊断测试和治疗方面存在差异. 然而,这些差异在调整为迷你精神状态考试 (MMSE) 成绩后并不显著.
科学领域:
- 老年学是一门学科.
- 公共卫生 公共卫生
- 神经学 神经学
背景情况:
- 痴呆症的诊断和治疗机会在不同的人群中可能有很大差异.
- 了解外国出生的个人在护理方面的差异对于公平的医疗保健至关重要.
- 以前的研究表明,移民人口在获得医疗保健方面存在潜在的不平等.
研究的目的:
- 调查外国出生的与瑞典出生的人口之间的痴呆症诊断测试和药物治疗的差异.
- 检查出生国对使用特定痴呆症药物的影响.
主要方法:
- 使用瑞典国家卫生登记册进行的回顾性队列研究.
- 瑞典出生的和外国出生的个人之间的痴呆症诊断测试率的比较.
- 基于出生国家的胆酶抑制剂和记忆剂处方模式的分析.
主要成果:
- 与瑞典出生的个人相比,外国出生的个人不太可能接受痴呆症诊断测试.
- 出生在非洲或欧洲的人接受胆酶抑制剂的可能性较低.
- 亚洲出生的个体显示胆酶抑制剂使用量增加,但记忆素使用量减少.
- 在微型精神状态检查 (MMSE) 成绩调整后,在痴呆症护理中观察到的差异并不总是存在.
结论:
- 在瑞典出生的和外国出生的人口之间,在痴呆症诊断和治疗方面存在显著差异.
- 出生的国家与对痴呆症药物的差异性获取有关.
- 出生国对痴呆症护理不平等的影响可能由认知状态介导,如MMSE得分所示.
相关概念视频
Dementia
115
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
115
Documentation in Long-Term and Home Healthcare Setting
893
Documentation in long-term care facilities and home healthcare settings is crucial for ensuring continuous, coordinated, and comprehensive care for patients. Each setting has its specific documentation processes and tools:
Long-Term Care Facilities
Long-Term Care Facilities
893
Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
Alzheimer's Disease: Overview
491
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
491

